公开(公告)号：US20210206760A1

公开(公告)日：2021-07-08

申请号：US17056466

申请日：2019-05-20

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Chuanwen YANG ,  Xiaojun WANG ,  Yinglin ZUO ,  Yingjun ZHANG ,  Jiancheng WANG ,  Hui WANG ,  Bo CHI

IPC: C07D471/04 ,  A61K45/06 ,  A61K31/4375 ,  A61K31/616

Abstract: A phenyl-substituted dihydronaphthyridine compound and use thereof, and further relates to a pharmaceutical composition including the compound. According to the present invention, the compound or the pharmaceutical composition can be used as a mineralocorticoid receptor antagonist.

公开(公告)号：US20210061839A1

公开(公告)日：2021-03-04

申请号：US16960488

申请日：2019-01-22

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Zheng GU ,  Wuyong WU ,  Tong QU ,  Panpan KANG ,  Zongyuan ZHANG ,  Weiming HUANG ,  Jianyu LIU ,  Yingjun ZHANG

IPC: C07H15/207

Abstract: A glucopyranosyl derivative as a sodium-dependent glucose transporters inhibitor, especially as a SGLT1 inhibitor, a pharmaceutically acceptable salt or a stereoisomer thereof, a pharmaceutical composition thereof, and the uses of the compound and pharmaceutical composition thereof in the preparation of drugs for the treatment of diabetes and diabetes-related diseases.

公开(公告)号：US20200339564A1

公开(公告)日：2020-10-29

申请号：US16474150

申请日：2018-01-04

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Qingyun REN ,  Changhua TANG ,  Junjun YIN ,  Kai YI ,  Yibo LEI ,  Yejun WANG ,  Yingjun ZHANG

IPC: C07D471/04 ,  C07D519/00 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/519 ,  A61P31/16 ,  A61K31/4965 ,  A61K31/404 ,  A61K31/7056 ,  A61K31/4172 ,  A61K47/64 ,  A61K31/5383 ,  A61K35/76

Abstract: Provided herein is inhibitors of influenza virus replication and uses thereof. Specifically, provided herein a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.

公开(公告)号：US20200283454A1

公开(公告)日：2020-09-10

申请号：US16646072

申请日：2018-09-18

Applicant: SUNSHINE LAKE PHARMA CO., LTD. ,  NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED

Inventor： Changhua TANG ,  Qingyun REN ,  Huichao LUO ,  Junjun YIN ,  Kai YI ,  Yibo LEI ,  Yejun WANG ,  Yingjun ZHANG

IPC: C07D498/14 ,  A61K31/5383 ,  A61K45/06 ,  A61K31/554 ,  A61P31/16

Abstract: Disclosed are a compound as shown in formula (I) as an influenza virus replication inhibitor and a preparation method therefor, a pharmaceutical composition comprising the compound and the use of the compound and pharmaceutical composition thereof in the treatment of influenza.

公开(公告)号：US20200276196A1

公开(公告)日：2020-09-03

申请号：US16646106

申请日：2018-09-21

Applicant: SUNSHINE LAKE PHARMA CO., LTD. ,  NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED

Inventor： Chuanfei JIN ,  Wenhe ZHONG ,  Haiping LIANG ,  Yingjun ZHANG

IPC: A61K31/506 ,  C07D401/14 ,  C07D403/14 ,  A61K45/06

Abstract: A substituted pyrimidine piperazine compound and uses thereof, and a pharmaceutical composition containing the compound and uses thereof. Wherein the compound has Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The substituted pyrimidine piperazine compound and the pharmaceutical composition containing the compound can be used to inhibit 5-hydroxytryptamine reuptake and/or activate the 5-HT1A receptors. Also, a method of preparing such compounds and pharmaceutical compositions, and uses thereof in the treatment of central nervous system dysfunction.

公开(公告)号：US20170044140A1

公开(公告)日：2017-02-16

申请号：US15107105

申请日：2015-01-22

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Yingjun ZHANG ,  Hongming XIE ,  Jiancun ZHANG ,  Bailin HU ,  Qinghong FANG ,  Qingyun REN

IPC: C07D403/14 ,  A61K31/4184 ,  A61K31/4178 ,  C07D405/14 ,  A61K45/06

CPC classification number: C07D403/14 ,  A61K31/4178 ,  A61K31/4184 ,  A61K45/06 ,  C07D405/14 ,  A61K2300/00

Abstract: Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions thereof in the treatment of HCV infection or hepatitis C.

Abstract translation: 本文提供了可用于治疗治疗性肝炎的式（I）的桥连式化合物或其立体异构体，互变异构体，N-氧化物，水合物，溶剂合物，代谢物，药学上可接受的盐或前药， C病毒（HCV）感染或丙型肝炎病毒。 本文还提供含有化合物的药物组合物和使用化合物或其药物组合物用于治疗HCV感染或其他炎症的方法。

公开(公告)号：US20160264562A1

公开(公告)日：2016-09-15

申请号：US15023676

申请日：2014-11-27

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Xinchang LIU ,  Qingyun REN ,  Zhifu ZOU ,  Jinsheng LIANG ,  Linjin TU ,  Siegfried GOLDMANN ,  Yingjun ZHANG

IPC: C07D417/04 ,  C07D417/14

CPC classification number: C07D417/04 ,  C07D417/14

Abstract: The present invention refers to processes for preparing a dihydropyrimidine compound having Formula (I), or a tautomer thereof having Formula (la), as well as a intermediate thereof. The process of the invention has simple operation, high optical purity of product, high yield and convenient work-up, which is suitable for industrial production.

公开(公告)号：US20220119382A1

公开(公告)日：2022-04-21

申请号：US17289192

申请日：2019-12-06

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Hongming XIE ,  Ming LUO ,  Jianli WU ,  Yingjun ZHANG ,  Yingchao CHENG

IPC: C07D471/04 ,  C07D519/00

Abstract: A RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, the present invention provides a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The invention also relates to a pharmaceutical composition including the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

公开(公告)号：US20210236493A1

公开(公告)日：2021-08-05

申请号：US17266961

申请日：2019-08-27

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Jianzhou HUANG ,  Qingyun REN ,  Jinfeng XIONG ,  Yang LIU ,  Xinchang LIU ,  Siegfried GOLDMANN ,  Yingjun ZHANG ,  Yifeng WANG ,  Weishun LIU ,  Fangcai YU

IPC: A61K31/5025 ,  A61K31/7068 ,  A61K31/675 ,  A61K38/21 ,  A61K38/20 ,  A61K31/7056 ,  A61K31/52 ,  A61K31/427 ,  A61K31/7072 ,  A61K31/429 ,  A61P31/20 ,  C07D471/04

Abstract: A fused tricyclic compound and application thereof in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B. Specifically, the present invention relates to a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variable is as defined in the specification. The present invention also relates to the use of a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B.

公开(公告)号：US20210054013A1

公开(公告)日：2021-02-25

申请号：US16965438

申请日：2019-01-29

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Zheng GU ,  Wuyong WU ,  Panpan KANG ,  Tong QU ,  Zongyuan ZHANG ,  Weiming HUANG ,  Tianyun WU ,  Yingjun ZHANG

IPC: C07H9/04 ,  A61K45/06 ,  A61K31/7048 ,  A61P3/10

Abstract: A glucopyranosyl derivative is used as an inhibitor of sodium-dependent glucose transporters (SGLTs), particularly being used as an inhibitor of sodium-dependent glucose transporter-1 (SGLT1), and a pharmaceutically acceptable salt or stereoisomer thereof, further relating to a pharmaceutical composition containing the derivative. The compound and a pharmaceutical composition is used thereof in the preparation of a drug for treating diabetes and diabetes-related diseases.